We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Survival rates following transplantation did not differ ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.

Mortality rates for pneumonia and pulmonary fibrosis have declined since 1999, but disparities persist by sex, race, and ...

Delayed IPF diagnosis often results in significant lung function impairment, impacting patient outcomes and increasing hospitalization rates. Antifibrotic therapies, nintedanib and pirfenidone, are ...

'Idiopathic Pulmonic Fibrosis (IPF)' is a disease in which lung tissue becomes harder and harder to breathe over time and can eventually threaten life. In particular, it is said to be fatal, with an ...

Patients with pulmonary fibrosis from the poorest areas had more severe symptoms by the time they saw a hospital doctor and had a poorer survival rate than those living in wealthier areas, according ...

Bacteria in the mouth may play a role in survival from idiopathic pulmonary fibrosis (IPF), finds a new study. Bacteria in the mouth may play a role in survival from idiopathic pulmonary fibrosis (IPF ...

July 9, 2009 — Interferon gamma-1b cannot be recommended as treatment in patients with idiopathic pulmonary fibrosis because it does not improve survival duration, according to the results of a ...

Higher levels of omega-3, the healthy fat found in fish and nuts, were associated with better lung function and longer transplant-free survival. Could healthy fats found in nuts and fish slow the ...

Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predicted forced vital capacity versus placebo ...

Tvardi Therapeutics has failed its first big test as a public company. Months after joining the Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in ...